Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

Aim: It is not well known how comorbidities may change the prognosis of atrial fibrillation (AF) patients. This study was aimed to analyze the impact of cardiovascular disease on this population. Materials & methods: EMIR was a multicenter, prospective study, including 1433 AF patients taking...

Full description

Bibliographic Details
Main Authors:	Francisco Marin, Marcelo Sanmartin Fernandez, Gonzalo Baron-Esquivias, Vivencio Barrios, Inaki Lekuona, Alejandro I Perez-Cabeza, Jaime Masjuan, Esther Recalde del Vigo, Jose Manuel Vazquez Rodriguez, Roman Freixa-Pamias, Vanessa Roldan Schilling, Fernando Arribas, Carles Rafols Priu, Manuel Anguita Sanchez
Format:	Article
Language:	English
Published:	Becaris Publishing Limited 2023-02-01
Series:	Journal of Comparative Effectiveness Research
Subjects:	atrial fibrillation bleeding coronary artery disease emir mace myocardial infarction peripheral artery disease rivaroxaban stroke vascular disease

Similar Items

Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice—Insights From the CANHEART Study
by: Maya S. Sheth, et al.
Published: (2022-12-01)

Outcomes with aspirin and clopidogrel versus aspirin and rivaroxaban in infrainguinal endovascular revascularization for critical limb ischemia
by: B Nishan, et al.
Published: (2021-01-01)

Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials
by: Debasu Z, et al.
Published: (2022-09-01)

Efficacy and Safety of Combination Therapy with Low-Dose Rivaroxaban in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Tommaso Bucci, et al.
Published: (2024-03-01)

Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study
by: Kerstin Jurk, et al.
Published: (2022-05-01)

Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease
by: N. V. Pogosova, et al.
Published: (2019-12-01)

Rivaroxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment in peripheral artery disease and analysis of medication utilization of different lesioned vascular regions
by: SiYan Huo, et al.
Published: (2023-11-01)

Spectrophotometric resolution for quantitative analysis of aspirin and rivaroxaban combination therapy in biological fluids using simple and eco-friendly procedure
by: Heba M. Mohamed, et al.
Published: (2024-02-01)

The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease
by: O. V. Averkov
Published: (2019-10-01)

Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease
by: Nikolaos P. E. Kadoglou, et al.
Published: (2022-09-01)

Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial
by: Zhong Yuan, et al.
Published: (2024-04-01)

Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial
by: José Luis Hernández, et al.
Published: (2020-07-01)

MODERN APPROACHES TO ANTICOAGULANT THERAPY OF PULMONARY EMBOLISM: FOCUS ON RIVAROXABAN
by: O. V. Averkov, et al.
Published: (2017-11-01)

Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells
by: Ryoichi Sohma, et al.
Published: (2023-06-01)

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Coronary Endarterectomy: A Cross Sectional Study
by: Foroud Shahbazi, et al.
Published: (2023-09-01)

Coronary Event Risk Test (CERT) as a Risk Predictor for the 10-Year Clinical Outcome of Patients with Peripheral Artery Disease
by: Andreas Leiherer, et al.
Published: (2023-09-01)

Perioperative cardiovascular outcome in patients with coronary artery disease undergoing major vascular surgery: A retrospective cohort study
by: Diana Thomas, et al.
Published: (2022-01-01)

The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization
by: Nikolaos P. E. Kadoglou, et al.
Published: (2021-11-01)

Up-to-date potential of antithrombotic therapy in patients with coronary artery disease and diabetes
by: O. D. Ostroumova, et al.
Published: (2020-09-01)

Effect of Rivaroxaban in Stroke Prevention in Patient with Atrial Fibrillation due to Valvular Heart Disease
by: Waqar shamim, et al.
Published: (2022-02-01)

Sex-Based Differences in Clinical Characteristics and Outcomes among Patients with Peripheral Artery Disease: A Retrospective Analysis
by: Giuseppe De Matteis, et al.
Published: (2023-08-01)

Incidence and impact of antiplatelet therapy cessation among very older patients with stable coronary artery disease
by: Xiao Zou, et al.
Published: (2023-06-01)

Effects of Metabolic Syndrome on Cardiovascular Outcomes of Psoriatic Patients with Coronary Artery Disease: A Single Center Retrospective Cohort Study
by: Zhao L, et al.
Published: (2023-04-01)

The Effects of Dabigatran and Rivaroxaban on Markers of Polymorphonuclear Leukocyte Activation
by: Guy A. Richards, et al.
Published: (2018-05-01)

Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events?
by: O. L. Barbarash, et al.
Published: (2020-09-01)

Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation
by: José Miguel Rivera-Caravaca, et al.
Published: (2021-07-01)

Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment
by: Giuseppe Di Tano, et al.
Published: (2020-06-01)

Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials
by: Jun Yuan
Published: (2018-05-01)

Hemomediastino en tomador de rivaroxaban
by: Pablo Ruiz-Sada, et al.
Published: (2016-12-01)

Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation
by: Manesh R. Patel, et al.
Published: (2018-03-01)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023-11-01)

The Prognostic Value of Thyroid-Stimulating Hormone in Patients with Coronary Artery Disease and Depression
by: Li W, et al.
Published: (2022-05-01)

Associations Among Depression, Hemoglobin A1c Level, and Prognosis in Patients With Coronary Artery Disease: A Prospective Study
by: Weiya Li, et al.
Published: (2022-06-01)

Major Adverse Cardiovascular Events in Coronary Type 2 Diabetic Patients: Identification of Associated Factors Using Electronic Health Records and Natural Language Processing
by: Carlos González-Juanatey, et al.
Published: (2022-10-01)

Acute Liver Failure after Treatment with Rivaroxaban for Aortic Thrombosis Associated with COVID-19 Infection and Methylenetetrahydrofolate Reductase Gene Polymorphism (C677T)
by: Ivana Jukic, et al.
Published: (2022-05-01)

The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases"
by: M. V. Zhuravleva, et al.
Published: (2022-03-01)

Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies
by: Manuel Anguita, et al.
Published: (2019-10-01)

Bullous pemphigoid‐like skin rash associated with Rivaroxaban use in a very elderly patient with multimorbidity and chronic kidney disease: A case report
by: Shakil Ahmed Chohan, et al.
Published: (2020-04-01)

Age-Specific Cardiovascular Risk Factors for Major Adverse Cardiac Events in Patients Undergoing Myocardial Perfusion Imaging
by: Rosario Megna, et al.
Published: (2023-09-01)

Prognostic value of N-terminal Pro–B-Type natriuretic peptide in patients with intermediate coronary lesions
by: Chenxi Song, et al.
Published: (2022-07-01)